Binary Events Abound in Biotech
Long Ideas - As most biotech enthusiasts will be well-aware of, biotech is rife with binary events this week, many of which fall on Tuesday April 30. While … Continue Reading
Read nowSearch Results for titan
Here’s What Happened at PropThink This Week
Long Ideas - Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King … Continue Reading
Read nowA Simple Strategy to Benefit from a Rare Biotech Situation: The Non-Halted AdCom
Most Popular - On the American equity exchanges, trading halts occur primarily for two reasons: news dissemination and extreme volatility. Halting an equity for a pending regulatory decision is often … Continue Reading
Read nowPropThink’s Weekend Healthcare Wrap-Up
Long Ideas - The EMA’s advisory body took investors by surprise on Friday and announced that they would be recommending Halozyme (HALO) and Baxter’s (BAX) HyQvia for approval … Continue Reading
Read nowPropThink’s Weekly Roundup
Most Popular - The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering … Continue Reading
Read nowPropThink’s Biotech and Healthcare Recap
Long Ideas - Happy Holidays from the team at PropThink! Our report on Trius Therapeutics tackled the short thesis, repudiating the focal points of the bear argument. Shares are, … Continue Reading
Read nowWeekly Recap: PropThink’s Latest in Healthcare and Biotech
Most Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read now